Market Overview

Piper Jaffray Provides Color on Biotechnology


Piper Jaffray provided color on biotechnology. In a research report published today, Piper Jaffray commented on two new drugs, Novo Nordisk's degludec and BMS and AstraZeneca's dapagliflozin.

In the report, Piper Jaffray states, “We attended the American Diabetes Association conference, where there was significant interest in Novo Nordisk's degludec (once daily insulin) and BMS and AstraZeneca's dapagliflozin, an SGLT2 inhibitor. Based on conversations with physicians' at the ADA, degludec has the potential to take share from Lantus and the combination of degludec and Victoza to expand the GLP-1 market. For dapagliflozin, imbalance in certain cancers and infection risk will be focus on FDA advisory panel meeting on July 19th.”

Posted-In: AstraZeneca BMS Novo Nordisk Piper JaffrayAnalyst Color Analyst Ratings


Related Articles

View Comments and Join the Discussion!

Latest Ratings

EVSIInitiates Coverage On9.0
RAMPInitiates Coverage On70.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Jefferies Provides Color on Aerospace and Defense Sector

Forex - EUR/USD rebounds from 7-day low as risk aversion wanes